Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CANbridge and WuXi Biologics Expand Rare Disease Partnership

publication date: Jan 8, 2019

CANbridge Pharma of Beijing and WuXi Biologics have added four drug candidates to their development partnership for rare diseases, which was originally announced three months ago. CANbridge will have exclusive regional or global rights to the biologic therapies. WuXi Biologics will receive upfront, milestone payments and royalties. CANbridge also announced that it in-licensed greater China rights to a treatment for Hunter syndrome, a rare disease, from Korea's GC Pharma (formerly Green Cross). More details....

Stock Symbols: (HK: 2269) (KRX: 006280)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.